Organon & Co. (OGN) To Go Ex-Dividend on February 24th

Organon & Co. (NYSE:OGN) declared a quarterly dividend on Thursday, February 13th,Wall Street Journal reports. Stockholders of record on Monday, February 24th will be given a dividend of 0.28 per share on Thursday, March 13th. This represents a $1.12 annualized dividend and a dividend yield of 7.32%. The ex-dividend date is Monday, February 24th.

Organon & Co. has increased its dividend payment by an average of 26.0% annually over the last three years. Organon & Co. has a payout ratio of 25.8% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Organon & Co. to earn $3.78 per share next year, which means the company should continue to be able to cover its $1.12 annual dividend with an expected future payout ratio of 29.6%.

Organon & Co. Trading Down 6.3 %

Organon & Co. stock opened at $15.30 on Friday. Organon & Co. has a one year low of $13.87 and a one year high of $23.10. The business’s fifty day moving average is $15.35 and its 200 day moving average is $17.48. The stock has a market capitalization of $3.94 billion, a PE ratio of 3.03, a price-to-earnings-growth ratio of 0.83 and a beta of 0.76. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. On average, sell-side analysts predict that Organon & Co. will post 3.82 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Barclays cut their price objective on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a report on Friday. Morgan Stanley reduced their price target on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a research report on Friday. Finally, TD Cowen raised shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $20.80.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.